{"id":"NCT03363854","sponsor":"LEO Pharma","briefTitle":"Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-22","primaryCompletion":"2019-03-08","completion":"2019-09-26","firstPosted":"2017-12-06","resultsPosted":"2021-01-14","lastUpdate":"2025-03-11"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tralokinumab(initial)responders-> Tralokinumab(continuation A)","type":"EXPERIMENTAL"},{"label":"Tralokinumab(initial)responders-> Tralokinumab(continuation B)","type":"EXPERIMENTAL"},{"label":"Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)","type":"EXPERIMENTAL"},{"label":"Placebo (initial)non-respon-> Tralokinumab(continuation A)","type":"EXPERIMENTAL"},{"label":"Placebo(initial)responders-> Placebo(continuation A)","type":"PLACEBO_COMPARATOR"}],"summary":"Primary objective:\n\nTo demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).\n\nSecondary objectives:\n\nTo evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared with placebo in combination with TCS.\n\nTo assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 32 weeks.","primaryOutcome":{"measure":"Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Tralokinumab Q2W+TCS","deltaMin":98,"sd":null},{"arm":"Placebo+TCS","deltaMin":33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":66,"countries":["United States","Belgium","Canada","Germany","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":["40879371","40555305","36152216","35857179"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":252},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Headache","Conjunctivitis","Dermatitis atopic"]}}